13th C1-inhibitor deficiency and angioedema workshop-2023 : Edited by: Róbert Hohol; Lectored by: Henriette Farkas, Lilian Varga; Cover artwork: Gergely Hosszú.

"Disclosures Disclosures: HF reports receiving research grants from CSL Behring, Shire/Takeda and Pharming and consultancy/speaker fees and honoraria from BioCryst Pharmaceuticals, Inc., CSL Behring, Pharming Group NV, KalVista and Shire HGT/Takeda and serves as an advisor and principal investigator for clinical trials/registries for BioCryst Pharmaceuticals, Inc., CSL Behring, Pharming, KalVista and Shire/Takeda. EAP received grants and/or fees as consultant or speaker for Biocryst, Centogene, CSL Behring, Kalvista, Pharming, Pharvaris and Shire/Takeda. AK research grants from Takeda and BioCryst, served on advisory boards for Takeda, BioCryst, Kalvista and CSL Behring and received speaker fees from Takeda and CSL Behring. FP has received speaker and advisory board funding from Takeda Pharmaceuticals, CSL Behring and principal investigator for clinical trials/registries for CSL Behring, Pharming, KalVista and Shire/Takeda. DGE does not have any disclosure. NB has received research grants from Takeda and Pharming and consultancy/speaker fees and honoraria from Pharming Group NV, KalVista and Shire HGT/Takeda and serves as an advisor and principal investigator for clinical trials for BioCryst Pharmaceuticals, Pharming, KalVista and Shire/Takeda. FG, NBE and IA are employees of Takeda and own Takeda stocks. LS is an employee of PPD, part of Thermo Fisher Scientific, Canada. The study is sponsored by Takeda Pharmaceuticals International AG. Medical writing support for the development of this abstract was provided by Pharmaceutical Product Development (PPD) and funded by Takeda Pharmaceuticals International AG. The authors retain full control of the abstract content. Special thanks to patients who participated in the study and all investigators for their contribution. Disclosures"